REDHILL BIOPHARMA LTD. (RDHL) Gross margin 2015–2024
REDHILL BIOPHARMA LTD. (RDHL) gross margin by fiscal year — reported gross profit divided by reported revenue.
60.3%FY2024 · since FY2015: 100.0% → 60.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | 60.3% | +13.3 pp |
| FY2023 | 47.0% | +1.0 pp |
| FY2022 | 46.1% | +3.7 pp |
| FY2021 | 42.4% | -0.3 pp |
| FY2020 | 42.7% | -21.4 pp |
| FY2019 | 64.1% | -2.0 pp |
| FY2018 | 66.1% | +19.1 pp |
| FY2017 | 46.9% | -53.1 pp |
| FY2016 | 100.0% | +0.0 pp |
| FY2015 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More RDHL financial trends
RDHL RevenueRDHL Net incomeRDHL Net marginRDHL Gross profitRDHL Operating incomeRDHL Operating marginRDHL Operating cash flowRDHL Free cash flowRDHL Capital expendituresRDHL Return on equityRDHL Stock buybacksRDHL Dividends paidRDHL Total assetsRDHL Total liabilitiesRDHL Shareholders’ equityRDHL overview →